-+ 0.00%
-+ 0.00%
-+ 0.00%

Cinclus Pharma completes Phase III HEEALING1 treatment period; topline data due Q4 2026

PUBT·09/02/2026 06:07:29
Listen to the news
Cinclus Pharma completes Phase III HEEALING1 treatment period; topline data due Q4 2026
  • Cinclus Pharma completed the eight-week treatment period in its Phase III HEEALING1 trial of linaprazan glurate for erosive GERD.
  • Topline results have not been presented yet; the readout is scheduled for Q4 2026 following a four-week safety follow-up.
  • The study is designed to show linaprazan glurate outperforms standard PPI therapy on healing, speed of healing, symptom control.
  • A positive outcome would support regulatory filings, underpinning Europe commercialization via Zentiva, while Cinclus retains US commercial rights.
  • A second Phase III trial, HEEALING2, is planned to start in the US and Europe after the HEEALING1 readout.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cinclus Pharma Holding AB (Publ) published the original content used to generate this news brief on September 02, 2026, and is solely responsible for the information contained therein.